Protein / target

Synaptotagmin-1

Encoded bySYT1P21579Homo sapiensSwiss-Prot

UniProt: P21579 Ensembl: ENSG00000067715 HGNC: HGNC:11509 NCBI Gene: 6857

Small-molecule tractable

Druggability

High-Quality Pocket

Research papers

Protein at a glance

Biological role

Low-density lipoprotein particle receptor binding

Strongest disease association

Genetic Diseases, Inborn

Via encoding gene SYT1 · Genetic evidence · score 0.74

Research activity

Emerging research

4 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Calcium sensor that participates in triggering neurotransmitter release at the synapse.

View complete UniProt function annotation

Calcium sensor that participates in triggering neurotransmitter release at the synapse (By similarity). May have a regulatory role in the membrane interactions during trafficking of synaptic vesicles at the active zone of the synapse (By similarity). It binds acidic phospholipids with a specificity that requires the presence of both an acidic head group and a diacyl backbone. A Ca(2+)-dependent interaction between synaptotagmin and putative receptors for activated protein kinase C has also been reported. It can bind to at least three additional proteins in a Ca(2+)-independent manner; these are neurexins, syntaxin and AP2. Plays a role in dendrite formation by melanocytes (PubMed:23999003)

Subcellular location

Cytoplasmic vesicle, secretory vesicle membraneCytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneCytoplasmic vesicle, secretory vesicle, chromaffin granule membraneCytoplasm

Domains and Gene Ontology detail (75)

Domains & features

C2 1C2 2

Gene Ontology

Caxon
Cchromaffin granule membrane
Cclathrin-coated endocytic vesicle membrane
Cclathrin-sculpted acetylcholine transport vesicle membrane
Cclathrin-sculpted gamma-aminobutyric acid transport vesicle membrane
Cclathrin-sculpted glutamate transport vesicle membrane
Cclathrin-sculpted monoamine transport vesicle membrane
Ccytoplasm
Cdense core granule
Cexcitatory synapse
Cexocytic vesicle
Cglutamatergic synapse

422 aa · 48 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Lipid & lipoprotein metabolismUniProt · GOExcitatory neurotransmissionGOInhibitory neurotransmissionGO

View supporting evidence

Lipid & lipoprotein metabolism

·Calcium sensor that participates in triggering neurotransmitter release at the synapse (…
·calcium-dependent phospholipid binding
·low-density lipoprotein particle receptor binding
·phospholipid binding

Excitatory neurotransmission

·excitatory synapse
·glutamatergic synapse
·regulation of synaptic transmission, glutamatergic

Inhibitory neurotransmission

·inhibitory postsynaptic potential

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene SYT1

Gene-level evidence surfaced through the gene SYT1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Genetic Diseases, Inborn

0.74Moderately supported

Genetic evidence dominant · Open Targets 0.45

Intelligence

0.70Moderately supported

Genetic evidence dominant · Open Targets 0.43

Spondylitis, Ankylosing

0.52Moderately supported

Genetic evidence dominant · Open Targets 0.32

Alcohol drinking

0.49Limited support

Genetic evidence dominant · Open Targets 0.30

Botulism

0.36Preliminary

Pathway evidence dominant · Open Targets 0.55 · no direct causal or clinical evidence

View evidence synthesis (5)

Genetic Diseases, InbornModerately supported

0.74

agreement 0.62–0.86

Genetic100%

Open Targets aggregate 0.45 · 1 independent evidence family

IntelligenceModerately supported

0.70

agreement 0.58–0.82

Genetic100%

Open Targets aggregate 0.43 · 1 independent evidence family

Spondylitis, AnkylosingModerately supported

0.52

agreement 0.40–0.64

Genetic100%

Open Targets aggregate 0.32 · 1 independent evidence family

Alcohol drinkingLimited support

0.49

agreement 0.35–0.63

Genetic98%Literature2%

Open Targets aggregate 0.30 · 2 independent evidence families

BotulismPreliminary

0.36

agreement 0.14–0.59

Pathway100%

Open Targets aggregate 0.55 · 1 independent evidence family · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Botulism0.55

Genetic Diseases, Inborn0.45

Intelligence0.43

Spondylitis, Ankylosing0.32

Alcohol drinking0.30

Tractability

Small molecules — Emerging

Feasibility evidence (high-quality pocket) — no clinical-stage drug of this modality recorded.

Antibodies — Emerging

Feasibility evidence (go cc high conf and uniprot sigp or tmhmm) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (5)

SM · High-Quality PocketAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

cocaine dependenceClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.